featured
AAN 2024: Monoclonal Antibody That Binds Alpha-Synuclein Slows Progression of Parkinson Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Pagano G, Taylor AI, Anzures-Cabrera J, et al. Trial of prasinezumab in early-stage Parkinson’s disease. N Engl J Med. 2022;387(5):421-432.
- Pagano G, Taylor KI, Anzures Cabrera J, et al. Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease. Nat Med. 2024;30(4):1096-1103.
- Pagano G, Monnet A, Reyes A, et al. Exploratory analysis of PASADENA Open-label extension evaluating the effect of Prasinezumab on the progression of motor signs and symptoms. Neurology. 2024;102(17_Suppl 1).
Disclosure statements are available on the authors' profiles: